08:14 AM EDT, 06/10/2024 (MT Newswires) -- Calidi Biotherapeutics ( CLDI ) said Monday that it signed a collaboration agreement with Siga Technologies ( SIGA ) in Q1 to support the development of Calidi's systemic and targeted RTNova virotherapy platform, which could potentially provide a universal treatment for all tumor types.

Calidi said it will initially focus on developing the RTNova platform for lung cancer and advanced stage solid tumors, which account for most cancer deaths.

Shares of Calidi Biotherapeutics ( CLDI ) surged more than 40% in recent premarket activity.

Price: 0.2753, Change: +0.08, Percent Change: +42.64